Full text is available at the source.
Abstract
Obesity among women of reproductive age is rising and significantly contributes to subfertility.
- Maternal obesity is associated with increased risks for complications during pregnancy and for the newborn.
- Preconception weight optimization is emphasized in clinical guidelines to mitigate risks for both mothers and infants.
- There is growing interest in the role of incretin-based anti-obesity medications in preconception care.
- Incidental exposure to these medications during early pregnancy is becoming more likely due to unplanned pregnancies.
- The review focuses on human evidence regarding GLP-1 and dual GLP-1/GIP receptor agonists for obesity treatment.
Simplified